$LXEOLexeo Therapeutics, Inc.

Active trials

• phase2Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathyrecruitingn=26
• —Clinical Course Of Disease In Participants With FA-CMrecruitingn=65
• phase2Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxiaactive not recruitingn=8
• —Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variantenrolling by invitationn=10
• phase2Gene Therapy for ACM Due to a PKP2 Pathogenic Variantactive not recruitingn=10
• phase2Gene Therapy for APOE4 Homozygote of Alzheimer's Diseasecompletedn=15
• phase1Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Diseaseactive not recruitingn=10
• —A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACMrecruitingn=40